why choose us

First received: January 30, 2023

Clinical Trial: Study of PYX-106 in Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors

Brief Summary: The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.

Read more